CAPROMAB PENDETIDE (PROSTASCINT®) IS THE MURINE MONOCLONAL ANTIBODY, 7E11-C5.3, CONJUGATED TO THE LINKER-CHELATOR, GLYCYL-TYROSYL-(N,?-DIETHYLENETRIAMINEPENTAACETIC ACID) LYSINE HYDROCHLORIDE (GYK-DTPA-HCL). THE 7E11-C5.3 ANTIBODY IS OF THE IGG1, KAPPA SUBCLASS (IGG1?). THIS ANTIBODY IS DIRECTED AGAINST A GLYCOPROTEIN EXPRESSED BY PROSTATE EPITHELIUM KNOWN AS PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA). THE PSMA EPITOPE RECOGNIZED BY MONOCLONAL ANTIBODY (MAB) 7E11-C5.3 IS LOCATED IN THE CYTOPLASMIC DOMAIN. EXPRESSION OF THIS GLYCOPROTEIN HAS NOT BEEN DEMONSTRATED ON ANY OTHER ADENOCARCINOMAS OR TRANSITIONAL CELL CANCERS TESTED.
PROSTATE SPECIFIC MEMBRANE ANTIGEN IS EXPRESSED IN MANY PRIMARY AND METASTATIC PROSTATE CANCER LESIONS, AND IN VITRO IMMUNOHISTOLOGIC STUDIES HAVE SHOWN 7E11-C5.3 TO BE REACTIVE WITH > 95% OF THE PROSTATE ADENOCARCINOMAS EVALUATED. IN GENERAL, PSMA EXPRESSION BY PROSTATE CANCER CELLS IS EITHER UNCHANGED OR INCREASED IN PATIENTS TREATED WITH HORMONAL THERAPY. THE 7E11-C5.3 ANTIBODY IS IMMUNOREACTIVE WITH NORMAL AND HYPERTROPHIC ADULT PROSTATE TISSUE. IN CLINICAL STUDIES OF PATIENTS WITH PROSTATE CANCER, INDIUM IN 111 PROSTASCINT® (CAPROMAB PENDETIDE) LOCALIZED TO THE PROSTATE, AND SOME KNOWN PRIMARY AND METASTATIC TUMOR SITES.